{
    "nctId": "NCT00005957",
    "briefTitle": "Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer",
    "officialTitle": "A Phase III Study of Regional Radiation Therapy in Early Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1832,
    "primaryOutcomeMeasure": "Overall Survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically proven invasive carcinoma of the breast\n\n  * No evidence of T4, N2-3, or M1 disease prior to surgery\n  * Node positive or high-risk node negative\n* Prior breast-conserving therapy (BCT) (e.g., lumpectomy, partial mastectomy, or segmental mastectomy) and axillary node dissection or sentinel node biopsy required and must be a candidate for breast radiotherapy after BCT\n\n  * Normally patients should have microscopically clear resection margins and those with positive margins should undergo reexcision\n  * Patients with microscopically focally positive margins (defined as no greater than 3 times high power fields) are candidates for breast radiotherapy plus a boost to the lumpectomy site\n  * Patients with prior sentinel node dissection eligible if node negative, but still meet high-risk criteria\n\n    * If node positive, then a level I and II axillary dissection must be performed\n  * No evidence of residual disease in axilla after dissection\n* Must be treated with currently accepted adjuvant systemic chemotherapy and/or hormonal therapy\n* High risk of regional and systemic recurrence due to one of the following:\n\n  * Pathologically positive axillary lymph nodes\n  * Pathologically negative axillary lymph nodes with one of the following:\n\n    * Primary tumor greater than 5 cm\n    * Primary tumor greater than 2 cm and less than 10 axillary lymph nodes excised and one of the following:\n\n      * Estrogen receptor negative\n      * Skarf-Bloom-Richardson grade 3\n      * Lymphovascular invasion\n* Hormone receptor status:\n\n  * Estrogen and progesterone receptor status known\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 16 and over\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Premenopausal or postmenopausal\n\nPerformance status:\n\n* ECOG 0-2\n\nLife expectancy:\n\n* At least 5 years\n\nHematopoietic:\n\n* Not specified\n\nHepatic:\n\n* SGOT and/or SGPT no greater than 3 times upper limit of normal (ULN)\\*\n* Alkaline phosphatase no greater than 3 times ULN\\* NOTE: \\* Patients with laboratory values greater than 3 times ULN may still be eligible if no metastatic disease by imaging examinations\n\nRenal:\n\n* No serious nonmalignant renal disease\n\nCardiovascular:\n\n* No serious nonmalignant cardiovascular disease\n\nPulmonary:\n\n* No serious nonmalignant pulmonary disease\n\nOther:\n\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No other serious nonmalignant disease (e.g., systemic lupus erythematosus or scleroderma) that would preclude definitive surgery or radiotherapy\n* No other malignancy except:\n\n  * Nonmelanomatous skin cancer\n  * Carcinoma in situ of the cervix or endometrium\n  * Contralateral noninvasive breast cancer (unless prior radiotherapy to the contralateral breast)\n  * Invasive carcinoma of the cervix, endometrium, colon, thyroid, or melanoma that was curatively treated at least 5 years prior to study participation\n* No psychiatric or addictive disorder that would preclude informed consent or study compliance\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Not specified\n\nChemotherapy:\n\n* See Disease Characteristics\n* Concurrent standard adjuvant chemotherapy allowed\n\nEndocrine therapy:\n\n* See Disease Characteristics\n* Concurrent standard adjuvant hormonal therapy allowed\n\nRadiotherapy:\n\n* See Disease Characteristics\n\nSurgery:\n\n* See Disease Characteristics",
    "sex": "FEMALE",
    "minimumAge": "16 Years",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}